Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $440M | $389M | $291M | $51M | $0M | $0M | $0M | $0M | $1M | $0M | $0M |
| Beneficio bruto | $411M | $360M | $270M | $48M | ($4M) | ($3M) | ($2M) | ($1M) | $1M | $0M | $0M |
| % de margen bruto | 93.4% | 92.6% | 93.1% | 93.9% | — | — | — | — | 86.3% | — | — |
| Ingresos operativos (EBIT) | $197M | $161M | $66M | ($110M) | ($145M) | ($68M) | ($33M) | ($22M) | ($12M) | ($5M) | ($1M) |
| % de margen operativo | 44.8% | 41.4% | 22.6% | -216.4% | — | — | — | — | -1160.3% | — | — |
| Ingresos netos | $241M | $205M | $89M | $11M | ($140M) | ($70M) | ($32M) | ($19M) | ($11M) | ($8M) | ($1M) |
| % de margen neto | 54.8% | 52.6% | 30.7% | 21.6% | — | — | — | — | -1060.3% | — | — |
| EBITDA | — | $196M | $110M | ($91M) | ($117M) | ($66M) | ($30M) | ($18M) | ($11M) | ($5M) | ($1M) |
| Beneficio por acción (EPS) | $8.00 | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | $-1.20 | $-0.97 | $-1.48 | $-0.27 |
| Acciones en circulación (M) | — | 30M | 30M | 28M | 25M | 22M | 19M | 16M | 11M | 5M | 4M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de KRYS. /companies/us/KRYS
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms